Equities research analysts expect Abeona Therapeutics Inc (NASDAQ:ABEO) to announce ($0.12) earnings per share for the current quarter, Zacks Investment Research reports. Three analysts have made estimates for Abeona Therapeutics’ earnings, with estimates ranging from ($0.13) to ($0.12). Abeona Therapeutics reported earnings of ($0.20) per share during the same quarter last year, which indicates a positive year-over-year growth rate of 40%. The firm is scheduled to issue its next quarterly earnings report on Tuesday, August 15th.
According to Zacks, analysts expect that Abeona Therapeutics will report full-year earnings of ($0.53) per share for the current fiscal year, with EPS estimates ranging from ($0.62) to ($0.44). For the next financial year, analysts anticipate that the business will report earnings of ($0.23) per share, with EPS estimates ranging from ($0.76) to $0.86. Zacks Investment Research’s earnings per share averages are a mean average based on a survey of sell-side research firms that that provide coverage for Abeona Therapeutics.
Abeona Therapeutics (NASDAQ:ABEO) last announced its earnings results on Thursday, May 18th. The biopharmaceutical company reported ($0.13) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.15) by $0.02. Abeona Therapeutics had a negative return on equity of 21.61% and a negative net margin of 2,820.97%. The business had revenue of $0.19 million for the quarter, compared to analyst estimates of $0.28 million.
Several research firms have recently commented on ABEO. Maxim Group set a $14.00 price target on shares of Abeona Therapeutics and gave the company a “buy” rating in a research note on Saturday, May 13th. HC Wainwright set a $20.00 price objective on shares of Abeona Therapeutics and gave the company a “buy” rating in a research note on Wednesday, July 19th. Zacks Investment Research raised shares of Abeona Therapeutics from a “hold” rating to a “buy” rating and set a $10.00 price objective on the stock in a research note on Tuesday, July 11th. BidaskClub raised shares of Abeona Therapeutics from a “hold” rating to a “buy” rating in a research note on Thursday, July 6th. Finally, Cantor Fitzgerald reaffirmed a “buy” rating and issued a $21.00 price objective on shares of Abeona Therapeutics in a research note on Tuesday, June 6th. Seven research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. The company presently has an average rating of “Buy” and an average price target of $17.86.
Shares of Abeona Therapeutics (ABEO) traded down 4.08% during mid-day trading on Monday, hitting $9.40. The stock had a trading volume of 678,498 shares. Abeona Therapeutics has a one year low of $2.42 and a one year high of $10.26. The company’s market cap is $378.40 million. The firm’s 50 day moving average price is $6.83 and its 200-day moving average price is $5.69.
COPYRIGHT VIOLATION NOTICE: “Brokerages Anticipate Abeona Therapeutics Inc (NASDAQ:ABEO) Will Post Earnings of -$0.12 Per Share” was reported by BNB Daily and is the property of of BNB Daily. If you are reading this piece of content on another site, it was copied illegally and republished in violation of US & international copyright and trademark laws. The correct version of this piece of content can be viewed at https://www.baseball-news-blog.com/2017/08/19/brokerages-anticipate-abeona-therapeutics-inc-nasdaqabeo-will-post-earnings-of-0-12-per-share-updated-updated-updated.html.
Institutional investors have recently made changes to their positions in the stock. Private Advisor Group LLC boosted its position in shares of Abeona Therapeutics by 50.0% in the first quarter. Private Advisor Group LLC now owns 21,005 shares of the biopharmaceutical company’s stock worth $108,000 after buying an additional 6,999 shares during the last quarter. Family Management Corp acquired a new position in shares of Abeona Therapeutics during the first quarter worth about $120,000. Hikari Power Ltd acquired a new position in shares of Abeona Therapeutics during the first quarter worth about $150,000. Tudor Investment Corp Et Al acquired a new position in shares of Abeona Therapeutics during the fourth quarter worth about $162,000. Finally, Segantii Capital Management Ltd boosted its position in shares of Abeona Therapeutics by 564.6% in the first quarter. Segantii Capital Management Ltd now owns 33,894 shares of the biopharmaceutical company’s stock worth $169,000 after buying an additional 28,794 shares during the last quarter. 35.64% of the stock is currently owned by hedge funds and other institutional investors.
Abeona Therapeutics Company Profile
Abeona Therapeutics Inc is a clinical-stage biopharmaceutical company developing novel gene therapies for life-threatening rare genetic diseases. The Company’s lead programs include ABO-102 (AAV-SGSH), an adeno-associated virus (AAV) based gene therapy for Sanfilippo syndrome type A (MPS IIIA) and EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB).
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Abeona Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abeona Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.